- Home
- CMMB vs TRT Comparison
CMMB vs TRT Comparison
Compare CMMB & TRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- TRT
- Stock Information
- Founded
- CMMB 2004
- TRT 1958
- Country
- CMMB Israel
- TRT United States
- Employees
- CMMB N/A
- TRT N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- TRT Industrial Machinery/Components
- Sector
- CMMB Health Care
- TRT Technology
- Exchange
- CMMB Nasdaq
- TRT Nasdaq
- Market Cap
- CMMB 23.6M
- TRT 25.2M
- IPO Year
- CMMB N/A
- TRT N/A
- Fundamental
- Price
- CMMB $1.16
- TRT $5.92
- Analyst Decision
- CMMB Strong Buy
- TRT
- Analyst Count
- CMMB 2
- TRT 0
- Target Price
- CMMB $9.00
- TRT N/A
- AVG Volume (30 Days)
- CMMB 153.9K
- TRT 5.1K
- Earning Date
- CMMB 03-03-2025
- TRT 05-12-2025
- Dividend Yield
- CMMB N/A
- TRT N/A
- EPS Growth
- CMMB N/A
- TRT N/A
- EPS
- CMMB N/A
- TRT 0.13
- Revenue
- CMMB N/A
- TRT $38,562,000.00
- Revenue This Year
- CMMB N/A
- TRT N/A
- Revenue Next Year
- CMMB N/A
- TRT N/A
- P/E Ratio
- CMMB N/A
- TRT $45.86
- Revenue Growth
- CMMB N/A
- TRT N/A
- 52 Week Low
- CMMB $0.58
- TRT $5.22
- 52 Week High
- CMMB $2.55
- TRT $7.88
- Technical
- Relative Strength Index (RSI)
- CMMB 31.89
- TRT 48.80
- Support Level
- CMMB $0.92
- TRT $6.10
- Resistance Level
- CMMB $1.35
- TRT $6.10
- Average True Range (ATR)
- CMMB 0.12
- TRT 0.20
- MACD
- CMMB -0.01
- TRT -0.02
- Stochastic Oscillator
- CMMB 24.79
- TRT 31.67
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About TRT Trio-Tech International
Trio-Tech International is a provider of third-party semiconductor testing and burn-in services through its laboratories in Southeast Asia. The company operates in four segments namely Manufacturing, Testing services, Distribution, and Real Estate. Its Manufacturing segment manufactures both front-end and back-end semiconductor test equipment and related peripherals. The Testing Services segment renders services to the manufacturer and purchaser of semiconductors and other entities. Its Distribution segment is involved in the distribution of its products. The company's Real Estate segment consists of investment in real estate. Its geographical area of operations includes the United States, Singapore, Malaysia, Thailand, and China. It derives maximum revenue from Testing services Segment.